8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Author(s):
Boerekamps, A.; Vanwolleghem, T.; Valk, M. van der; Berk, G.E. van den; Kasteren, M. van; Posthouwer, D.; Dofferhoff, A.S.M.; Hoek, B. van (0000-0001-6527-764X); Ramsoekh, D.; Koopsen, J.; Schinkel, J.; Florence, E.; Arends, J.E.; Rijnders, B.J.
Published
2019
Publication type
Article / Letter to editor
Date issued
2019-03-31
Language
English
Is part of
Journal of Hepatology (2019), Vol. 70, no. 3, p. 554-557
hdl
1887/119671
doi
10.1016/j.jhep.2018.10.032